On September 1, 2025, Novo Nordisk presented data from the STEER real-world study at the European Society of Cardiology Congress. The study demonstrated that Wegovy (semaglutide 2.4 mg) significantly reduced the risk of major adverse cardiovascular events (MACE) compared with Eli Lilly's tirzepatide.
The STEER study, which gathered evidence from actual patient experiences, investigated the risk of heart attack, stroke, or cardiovascular-related death in people with overweight or obesity and established cardiovascular disease without diabetes. Wegovy showed a significant 57% greater risk reduction compared to tirzepatide for patients on continuous treatment.
This superior cardiovascular profile reinforces Wegovy's differentiated benefits beyond weight reduction, providing a strong competitive advantage. The data further solidifies Novo Nordisk's position in the metabolic health market by highlighting the comprehensive health improvements offered by its flagship obesity treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.